DMK Pharmaceuticals Corporation
OTC: DMKPQ0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- Other OTC
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- CEO
- Eddie Wabern Glover
- Employees
- 11
- Headquarters
- San Diego, United States
- IPO year
- 1995
- Market cap
- $1.0K
- Website
- https://www.dmkpharmaceuticals.com
Loading DMKPQ…
Loading profile data…Frequently asked questions about DMKPQ
What does DMK Pharmaceuticals Corporation (DMKPQ) do?
DMK Pharmaceuticals Corporation functions as a clinical-stage neuro-biotechnology company, focusing on the development and market introduction of therapeutic solutions across several medical fields, including allergies, opioid overdose, respiratory conditions, and inflammatory diseases. Its primary product candidate currently in clinical trials...
Where does DMKPQ trade?
DMK Pharmaceuticals Corporation (DMKPQ) trades on the Other OTC.
What sector is DMKPQ in?
DMK Pharmaceuticals Corporation (DMKPQ) operates in the Healthcare sector, specifically in the Drug Manufacturers - Specialty & Generic industry.
Who is the CEO of DMK Pharmaceuticals Corporation?
Eddie Wabern Glover is the chief executive officer of DMK Pharmaceuticals Corporation (DMKPQ).
Where is DMK Pharmaceuticals Corporation headquartered?
DMK Pharmaceuticals Corporation is headquartered in United States.
Does DMKPQ pay a dividend?
DMK Pharmaceuticals Corporation (DMKPQ) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did DMKPQ go public?
DMK Pharmaceuticals Corporation (DMKPQ) completed its initial public offering in 1995.